Chimeric: Media Thread, page-687

This could be great timing for CHM 2101.

Merck are losing patent protection for Keytruda in 2028 in the United States and in 2031 in Europe. Keytruda treats 16 types of cancer, one treatment is a form of colorectal cancer and another is for HER2-negative gastric cancer.

https://www.fiercepharma.com/pharma/merck-ceo-davis-dubs-keytruda-loe-more-hill-cliff
https://www.keytruda.com/

In the first quarter Keytruda accounted for 44% of Merck's revenue.

-Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 12%

-KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 24%

https://www.businesswire.com/news/home/20240425889273/en/Merck-Announces-First-Quarter-2024-Financial-Results

Last November the FDA granted approval for Merck’s Keytruda combo for gastric cancer. Its a first line therapy in combination with chemotherapy. Trial data has shown that the combination treatment reduced mortality risk by 22% versus chemotherapy alone.

https://www.pharmaceutical-technology.com/news/fda-approval-merck-keytruda/

I dare say Merck are keeping a very close eye on how CHM 2101 progresses.